Protalix BioTherapeutics, Inc.
PLX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14% | 54.8% | -44.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 53.4% | 62.5% | 19.1% | 78.7% |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 15.6% | 11.5% | -33.4% | 42% |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 13.2% | 1% | -35.8% | 35.6% |
| EPS Diluted | 0.03 | 0.002 | -0.047 | 0.086 |
| % Growth | 1,400% | 104.2% | -155.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |